Recombinant antibodies and fragments which recognize n glycolil gm3 ganglioside and its use in diagnosis and treatment of tumours
CA 2523449 C · Owner: Moreno Frias, Ernesto · Inventors: Rodriguez Gonzalez, Mabel; Roque Navarro, Loudes Tatiana; Talavera Perez, Ariel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention essentially relates to the production of less immunogenic immunoglobulins by means of genetic engineering and more specifically, to a , monoclonal antibody recognising antigens which contain ganglioside N-glycolyl- GM3 but not other N-glycolyl- or N-acetyl-type gangliosides nor sulphated glycolipids. In particular, the invention relates to peptide sequences encoding a recombinant monoclonal antibody against ganglioside N-glycolyl-GM3 or derivative fragments of same. The invention further relates to pharmaceutical compositions containing the aforementioned antibody or fragments thereof and to the diagnostic or therapeutic use of same for breast cancer and melanoma.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 22, 2004 and granted September 18, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 22, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 22, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.